Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study

After an FDA rejection last year, Aldeyra Therapeutics has scored a clinical win for dry eye drug reproxalap, which significantly reduced ocular discomfort in a new phase 3 study.